Citigroup’s Myriad Genetics MYGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$667K Buy
116,820
+99,813
+587% +$453K ﹤0.01% 3742
2026
Q1
$76.5K Sell
17,007
-18,923
-53% -$98.6K ﹤0.01% 4374
2025
Q4
$221K Sell
35,930
-43,565
-55% -$316K ﹤0.01% 3954
2025
Q3
$575K Sell
79,495
-44,258
-36% -$263K ﹤0.01% 3509
2025
Q2
$657K Sell
123,753
-119,836
-49% -$708K ﹤0.01% 3453
2025
Q1
$2.16M Buy
243,589
+51,351
+27% +$617K ﹤0.01% 2630
2024
Q4
$2.64M Buy
192,238
+74,056
+63% +$1.37M ﹤0.01% 2577
2024
Q3
$3.24M Buy
118,182
+35,204
+42% +$953K ﹤0.01% 2235
2024
Q2
$2.03M Sell
82,978
-184,128
-69% -$4.04M ﹤0.01% 2341
2024
Q1
$5.69M Buy
267,106
+147,679
+124% +$3.17M ﹤0.01% 1616
2023
Q4
$2.29M Sell
119,427
-2,353
-2% -$40.7K ﹤0.01% 2130
2023
Q3
$1.95M Buy
121,780
+5,799
+5% +$110K ﹤0.01% 1998
2023
Q2
$2.69M Sell
115,981
-59,092
-34% -$1.29M ﹤0.01% 1947
2023
Q1
$4.07M Buy
175,073
+32,890
+23% +$668K ﹤0.01% 1609
2022
Q4
$2.06M Sell
142,183
-55,320
-28% -$1.03M ﹤0.01% 2014
2022
Q3
$3.77M Buy
197,503
+48,282
+32% +$1.11M ﹤0.01% 1707
2022
Q2
$2.71M Buy
149,221
+42,537
+40% +$883K ﹤0.01% 1898
2022
Q1
$2.69M Sell
106,684
-107,972
-50% -$2.76M ﹤0.01% 2111
2021
Q4
$5.92M Buy
214,656
+81,995
+62% +$2.38M ﹤0.01% 1701
2021
Q3
$4.28M Sell
132,661
-70,370
-35% -$2.34M ﹤0.01% 1931
2021
Q2
$6.21M Buy
203,031
+61,974
+44% +$1.79M ﹤0.01% 1736
2021
Q1
$4.3M Buy
141,057
+93,915
+199% +$2.67M ﹤0.01% 1886
2020
Q4
$932K Buy
47,142
+16,976
+56% +$274K ﹤0.01% 3605
2020
Q3
$393K Sell
30,166
-120,551
-80% -$1.53M ﹤0.01% 4060
2020
Q2
$1.71M Buy
150,717
+23,206
+18% +$330K ﹤0.01% 2994
2020
Q1
$1.82M Buy
127,511
+71,221
+127% +$1.5M ﹤0.01% 2565
2019
Q4
$1.53M Sell
56,290
-73,228
-57% -$2.01M ﹤0.01% 3286
2019
Q3
$3.71M Buy
129,518
+49,545
+62% +$1.44M ﹤0.01% 2215
2019
Q2
$2.22M Sell
79,973
-2,381
-3% -$67.2K ﹤0.01% 2742
2019
Q1
$2.73M Sell
82,354
-143,995
-64% -$4.38M ﹤0.01% 2344
2018
Q4
$6.58M Buy
226,349
+211,259
+1,400% +$7.6M 0.01% 1593
2018
Q3
$694K Buy
15,090
+8,170
+118% +$363K ﹤0.01% 3883
2018
Q2
$258K Buy
6,920
+504
+8% +$17K ﹤0.01% 4795
2018
Q1
$189K Sell
6,416
-112,463
-95% -$3.81M ﹤0.01% 5028
2017
Q4
$4.08M Buy
118,879
+19,748
+20% +$666K ﹤0.01% 2026
2017
Q3
$3.59M Sell
99,131
-63,187
-39% -$1.8M ﹤0.01% 2062
2017
Q2
$4.2M Buy
162,318
+27,107
+20% +$575K ﹤0.01% 1848
2017
Q1
$2.6M Sell
135,211
-250,341
-65% -$4.44M ﹤0.01% 2216
2016
Q4
$6.43M Buy
385,552
+363,402
+1,641% +$6.57M 0.01% 1569
2016
Q3
$456K Buy
22,150
+5,645
+34% +$143K ﹤0.01% 3975
2016
Q2
$505K Sell
16,505
-49,200
-75% -$1.71M ﹤0.01% 3651
2016
Q1
$2.46M Buy
65,705
+51,640
+367% +$1.95M ﹤0.01% 2266
2015
Q4
$607K Sell
14,065
-12,965
-48% -$548K ﹤0.01% 3655
2015
Q3
$1.01M Buy
27,030
+7,505
+38% +$266K ﹤0.01% 3075
2015
Q2
$664K Buy
19,525
+3,060
+19% +$104K ﹤0.01% 3454
2015
Q1
$583K Sell
16,465
-13,800
-46% -$494K ﹤0.01% 3588
2014
Q4
$1.03M Buy
30,265
+15,609
+107% +$554K ﹤0.01% 3105
2014
Q3
$565K Buy
14,656
+5,611
+62% +$209K ﹤0.01% 3445
2014
Q2
$352K Sell
9,045
-322
-3% -$12K ﹤0.01% 3693
2014
Q1
$320K Buy
9,367
+1,435
+18% +$44.5K ﹤0.01% 3898
2013
Q4
$167K Sell
7,932
-10,050
-56% -$254K ﹤0.01% 4812
2013
Q3
$422K Buy
17,982
+16,061
+836% +$456K ﹤0.01% 3569
2013
Q2
$52K Buy
+1,921
New +$55.7K ﹤0.01% 5363

Other funds holding MYGN

Citigroup's MYGN Position: Q2 2026 in Review

Citigroup increased its Myriad Genetics (MYGN) stake by 587% in Q2 2026, buying an estimated $453K and bringing the position to 116,820 shares worth $667K. The position accounts for ﹤0.01% of the portfolio, ranked #3742.

Citigroup first reported a position in MYGN in Q2 2013 and has held it in 53 quarters since. The position peaked at $6.58M in Q4 2018. 196 funds tracked by Wall St. Rank hold MYGN as of Q2 2026.

  • Citigroup held 116,820 shares of Myriad Genetics worth $667K as of Q2 2026.
  • Citigroup bought 99,813 Myriad Genetics shares in Q2 2026, an estimated $453K.
  • Myriad Genetics made up ﹤0.01% of Citigroup's portfolio in Q2 2026, its #3742 holding.
  • Citigroup first reported a position in Myriad Genetics in Q2 2013 and has held it in 53 quarters since.
  • Citigroup's Myriad Genetics position peaked at $6.58M in Q4 2018.
  • 196 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.